[EN] SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS SUBSTITUÉS PAR PYRIDINYLE ET LEURS UTILISATIONS
申请人:BIONOMICS LTD
公开号:WO2019222816A1
公开(公告)日:2019-11-28
The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
[EN] COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS D'ASIC ET UTILISATIONS DE CEUX-CI
申请人:MERCK PATENT GMBH
公开号:WO2017045751A1
公开(公告)日:2017-03-23
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.
本发明涉及化合物及其药学上可接受的组合物,用作ASIC抑制剂。
Azepine inhibitors of Janus kinases
申请人:Arvanitis G. Argyrios
公开号:US20070149506A1
公开(公告)日:2007-06-28
The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy.